European Network of Vaccine Research and Development

TRANSVAC aims to accelerate the pharmaceutical and clinical development of promising vaccine candidates by bridging the gap between academic research and clinical trails through carefully managing the advancement of promising vaccine candidates from preclinical animal experiments to early proof-of principle studies in humans. Transvac will be the European driving force for vaccine development and will be open and accessible to those interested parties, who are capable of contributing key elements of the strategy, allowing them to leverage the value of the whole consortium. This consortium will comprise the major European stakeholders with an interest in vaccine development, from the scientific community in Europe to the European vaccine manufacturers. 


European Vaccine Initiative (EVI), Germany

Biomedical Primate Research Centre (BPRC), The Netherlands

Helmholtz Centre for Infection Research (HZI), Germany

Vakzine Projekt Management GmbH (VPM), Germany

LIONEX GmbH, Germany

ID-Lelystad (IDL), The Netherlands

UK Health Protection Agency, Centre for Emergency Preparedness and Response (CEPR, formerly CAMR), UK

UK Health Protection Agency, National Institute for Biological Standards and Control (NIBSC), UK

Max Planck Institute for Infection Biology (MPIIB), Germany

University of Regensburg (UREG), Germany

London School of Hygiene & Tropical Medicine (LSHTM), UK

University of Oxford, The Jenner Institute  (UOXF), UK

University of Lausanne (UNIL), Switzerland

TuBerculosis Vaccine Initiative (TBVI), The Netherlands


Beteiligte Gruppen


Carlos Guzman


European Vaccine Initiative (DE)


Geldgeber / Förderer

EU - Europäische Union